Liquid biopsies in metastatic renal cell carcinoma (mRCC) provide a unique approach to understand the molecular basis of treatment response and resistance. This is particularly important in the context of immunotherapies, which target key immune-tumor interactions. Unlike metastatic tissue biopsies, serial real-time profiling of mRCC is feasible with our noninvasive circulating tumor cell (CTC) approach.
We collected 457 longitudinal liquid biopsies from 104 patients with mRCC enrolled in one of two studies, either a prospective cohort or a phase II multicenter adaptive immunotherapy trial. Using a novel CTC capture and automated microscopy platform, we profiled CTC enumeration and expression of HLA I and programmed cell death-ligand 1 (PD-L1). Given their diametric immunological roles, we focused on the HLA I to PD-L1 ratio (HP ratio).
Patients with radiographic responses showed significantly lower CTC abundances throughout treatment. Furthermore, patients whose CTC enumeration trajectory was in the highest quartile (> 0.12 CTCs/mL annually) had shorter overall survival (median 17.0 months v 21.1 months, P < .001). Throughout treatment, the HP ratio decreased in patients receiving immunotherapy but not in patients receiving tyrosine kinase inhibitors. Patients with an HP ratio trajectory in the highest quartile (≥ 0.0012 annually) displayed significantly shorter overall survival (median 18.4 months v 21.2 months, P = .003).
In the first large longitudinal CTC study in mRCC to date to our knowledge, we identified the prognostic importance of CTC enumeration and the change over time of both CTC enumeration and the HP ratio. These insights into changes in both tumor burden and the molecular profile of tumor cells in response to different treatments provide potential biomarkers to predict and monitor response to immunotherapy in mRCC.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 May 26 [Epub ahead of print]
Matthew Bootsma, Rana R McKay, Hamid Emamekhoo, Rory M Bade, Jennifer L Schehr, Matthew C Mannino, Anupama Singh, Serena K Wolfe, Zachery D Schultz, Jamie Sperger, Wanling Xie, Sabina Signoretti, Christos E Kyriakopoulos, David Kosoff, Edwin J Abel, Kyle T Helzer, Nicholas Rydzewski, Hamza Bakhtiar, Yue Shi, Grace Blitzer, Michael Bassetti, John Floberg, Menggang Yu, Nan Sethakorn, Marina Sharifi, Paul M Harari, Toni K Choueiri, Joshua M Lang, Shuang G Zhao
Department of Human Oncology, University of Wisconsin-Madison, Madison, WI., Moores Cancer Center, University of California San Diego, La Jolla, CA., Department of Medicine, University of Wisconsin-Madison, Madison, WI., Dana-Farber Cancer Institute, Boston, MA., Urology, University of Wisconsin-Madison, Madison, WI., Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, WI.